Product
Lanreotide
Aliases
Lanreotide ATG, Lanreotide autogel, Lanreotide Autogel, lanreotide (Autogel formulation) (3 other aliases)
Name
SOMATULINE DEPOT
INN Name
lanreotide acetate
FDA Approved
Yes
12 clinical trials
1 organization
15 indications
1 document
Indication
GEP-NETIndication
Neuroendocrine TumorsIndication
Neuroendocrine tumorIndication
Carcinoid TumorIndication
Pancreatic Neuroendocrine TumorIndication
Carcinoid SyndromeIndication
AcromegalyIndication
Endocrine TumorsIndication
Gastrointestinal NeoplasmsIndication
Carcinoid TumorsClinical trial
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NETStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA TherapyStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid SyndromeStatus: Completed, Estimated PCD: 2013-05-01
Clinical trial
Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine TumourStatus: Completed, Estimated PCD: 2015-12-01
Clinical trial
Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg AloneStatus: Completed, Estimated PCD: 2008-10-01
Clinical trial
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine TumourStatus: Completed, Estimated PCD: 2013-04-01
Clinical trial
A Phase 3, Single-arm, Open-label, Multicentre Study to Assess the Efficacy and Safety of Deep Subcutaneous Injections of Lanreotide Autogel® 120 mg Administered Every 28 Days in Chinese Participants With Unresectable, Locally Advanced or Metastatic Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs)Status: Completed, Estimated PCD: 2022-06-10
Clinical trial
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)Status: Terminated, Estimated PCD: 2022-05-27
Clinical trial
A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine TumorsStatus: Completed, Estimated PCD: 2023-04-10
Clinical trial
Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine TumorsStatus: Completed, Estimated PCD: 2021-05-03
Clinical trial
A Phase I/II Study Using Cabozantinib and Lanreotide as Treatment for Advanced Gastroenteropancreatic Neuroendocrine Tumors That Failed Molecular Targeted Therapies or Chemotherapy (SCALET)Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
Prospective Observational Study to Assess the Effectiveness and Safety of Lanreotide Autogel® in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Asia RegionStatus: Recruiting, Estimated PCD: 2024-01-30
Document
DailyMed Label: SOMATULINE DEPOTOrganization
Ipsen Biopharmaceuticals, Inc.